Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436810 | 0.85 | ALDH1A1 (0.44) | KDM4EALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL31628357 | 0.84 | KIF11 (0.55) | KDM4EALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL8506970 | 0.84 | KIF11 (0.55) | KDM4EALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL8507142 | 0.80 | RXFP1 (0.47) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL27457013 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL8506829 | 0.78 | PDE5A (0.53) | KDM4EALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL8504232 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL31628536 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL29624610 | 0.76 | MAPT (0.59) | KDM4EALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL28661005 | 0.76 | MAPT (0.59) | KDM4EALDH1A1KMT2AHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0750621-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1999-07-21 | — | — | EP | claimed |
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2006015263-A2 | LONIDAMINE ANALOGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0750621-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1999-07-21 | — | — | EP | disclosed |
| CN-1144529-A | Heterocyclic compounds, their preparation and use | NOVO NORDISK AS (DK) | 1997-03-05 | — | — | CN | disclosed |
| EP-0750621-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-01-02 | — | — | EP | disclosed |
| US-5536721-A | Thieno[2,3-b-indole derivatives and their use for treating central nervous system diseases related to the metabotropic glutamate receptor system | NOVO NORDISK A/S (DK) | 1996-07-16 | — | — | US | disclosed |
| WO-1995025110-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | KDM4E 4589/4885ALDH1A1 184/4885KMT2A 3513/4885 |
| US-20070043057-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | KDM4E 4589/4885ALDH1A1 184/4885KMT2A 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.